ItHome Hypertension CardieX (ASX:CDX) subsidiary granted European blood pressure patent

CardieX (ASX:CDX) subsidiary granted European blood pressure patent

Credits to the 👉🏾Source Link👉🏾 Olivia
CardieX (ASX:CDX) subsidiary granted European blood pressure patent
  • CardieX’s (CDX) subsidiary, ATCOR, has been granted a new patent by the European Patent Office (EPO) for its SphygmoCor technology
  • This technology enables non-invasive measurement of artery stiffness through central arterial pressure waveform and blood pressure analysis
  • The new patent further protects CardieX’s intellectual property (IP), specifically covering the non-invasive measurement of the heart’s pressure
  • The grant of the European patent follows on from similar patents already granted in the U.S. and Japan in 2016
  • CardieX is up a healthy 16.3 per cent and shares are trading for 5.7 cents

CardieX’s (CDX) subsidiary, ATCOR, has been granted a new patent by the European Patent Office (EPO) for its SphygmoCor technology.

The SphygmoCor technology enables non-invasive measurement of artery stiffness through central arterial pressure waveform and blood pressure analysis.

It has more than 4500 installations worldwide and is used by major pharmaceutical companies and research institutions such as The Mayo Clinic, Stanford University, and Johns Hopkins.

The new patent further protects CardieX’s intellectual property (IP), specifically covering the non-invasive measurement of the heart’s pressure and waveform.

This patent provides a non-invasive, simple, and operator-independent tool to clinically diagnose the cardiovascular system and estimate the risk of having heart disease.

The granting of the European patent follows on from similar patents already granted in the United States and Japan in 2016.

“We are very pleased to be granted this new patent to protect our IP in Europe,” CEO and Managing Director Craig Cooper said.

“Of great significance is the findings of the examining officers from the EPO, which were similar to the findings we received from examiners in the U.S. in 2016 – that there are substantial differences in respect of any other existing patents – further demonstrating and validating the uniqueness of our technology,” he added.

CardieX is up a healthy 16.3 per cent and shares are trading for 5.7 cents at 2:00 pm AEST.



Source Link

related posts

Leave a Comment

This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

%d bloggers like this: